Arbutus Biopharma Corporation (ABUS)
| Market Cap | 370.38M |
| Revenue (ttm) | 33.37M |
| Net Income (ttm) | -76.10M |
| Shares Out | 149.95M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 786,261 |
| Open | 2.52 |
| Previous Close | 2.50 |
| Day's Range | 2.44 - 2.53 |
| 52-Week Range | 1.93 - 6.50 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | 6.63 (+168.4%) |
| Earnings Date | Aug 4, 2022 |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid... [Read more...]
Financial Performance
In 2021, ABUS's revenue was $10.99 million, an increase of 58.92% compared to the previous year's $6.91 million. Losses were -$76.25 million, 19.6% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 168.42% from the latest price.
News
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor
Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences' core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the St...
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB...
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET
Arbutus to Participate in June Investor Conferences
WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual M...
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel th...
Arbutus to Present at H.C. Wainwright Global Investment Conference
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel th...
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel ...
This 1 New Threat Could Punish Moderna Stock
A new chapter of a long-standing legal battle is starting.
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022
Arbutus, Genevant sue Moderna, citing patent infringement
Shares of Arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the company said it is suing Moderna Inc. MRNA, +1.70% for infringing on several patents that relate to M...
Arbutus files patent infringement lawsuit against Moderna
Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna
VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (...
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel t...
What's the Outlook for Arbutus Biopharma?
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...